Anuh Pharma Ltd
Established in 1960, Anuh Pharma Ltd., a Bulk Drugs Manufacturing Company, is one of the largest manufacturers of Macrolides and Anti-TB products
in India, besides being a major player in Anti-Bacterial, Anti-Malarial, and Corticosteroids. The company is part of the INR 8.5 bn SK Group of Companies, which employs 2000+ people across businesses such as Manufacturing of API's, medicinal chemical and botanical products, Pharma Formulations, Distribution and Logistics (primarily for large MNC brands)
- Market Cap ₹ 1,266 Cr.
- Current Price ₹ 253
- High / Low ₹ 265 / 87.1
- Stock P/E 21.1
- Book Value ₹ 58.1
- Dividend Yield 0.79 %
- ROCE 29.4 %
- ROE 22.6 %
- Face Value ₹ 5.00
Pros
- Company is almost debt free.
- Company has delivered good profit growth of 22.3% CAGR over last 5 years
- Company has been maintaining a healthy dividend payout of 25.8%
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
243 | 266 | 284 | 326 | 206 | 238 | 321 | 307 | 432 | 487 | 527 | 647 | |
225 | 242 | 253 | 289 | 183 | 220 | 291 | 284 | 387 | 439 | 476 | 572 | |
Operating Profit | 18 | 24 | 31 | 38 | 23 | 18 | 30 | 23 | 45 | 47 | 52 | 75 |
OPM % | 7% | 9% | 11% | 12% | 11% | 8% | 9% | 8% | 10% | 10% | 10% | 12% |
2 | 4 | 5 | 4 | 8 | 7 | 5 | 4 | 11 | 5 | 6 | 12 | |
Interest | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 2 | 2 | 1 | 0 |
Depreciation | 2 | 2 | 3 | 2 | 2 | 2 | 2 | 7 | 15 | 12 | 10 | 9 |
Profit before tax | 18 | 25 | 32 | 38 | 28 | 23 | 32 | 19 | 39 | 39 | 47 | 78 |
Tax % | 29% | 31% | 31% | 32% | 27% | 29% | 28% | 25% | 26% | 22% | 24% | 23% |
13 | 18 | 22 | 26 | 20 | 17 | 23 | 14 | 28 | 31 | 36 | 60 | |
EPS in Rs | 2.50 | 3.51 | 4.39 | 5.15 | 4.00 | 3.30 | 4.66 | 2.86 | 5.68 | 6.10 | 7.22 | 11.99 |
Dividend Payout % | 40% | 37% | 27% | 24% | 31% | 42% | 29% | 48% | 26% | 29% | 28% | 21% |
Compounded Sales Growth | |
---|---|
10 Years: | 9% |
5 Years: | 15% |
3 Years: | 14% |
TTM: | 23% |
Compounded Profit Growth | |
---|---|
10 Years: | 14% |
5 Years: | 22% |
3 Years: | 39% |
TTM: | 82% |
Stock Price CAGR | |
---|---|
10 Years: | 24% |
5 Years: | 32% |
3 Years: | 18% |
1 Year: | 175% |
Return on Equity | |
---|---|
10 Years: | 15% |
5 Years: | 15% |
3 Years: | 17% |
Last Year: | 23% |
Balance Sheet
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 4 | 4 | 4 | 13 | 13 | 13 | 13 | 13 | 25 | 25 | 25 | 25 |
Reserves | 71 | 82 | 97 | 107 | 128 | 137 | 152 | 150 | 166 | 189 | 216 | 266 |
1 | 0 | 0 | 2 | 0 | 2 | 4 | 45 | 14 | 4 | 1 | 3 | |
60 | 77 | 67 | 71 | 48 | 57 | 71 | 119 | 128 | 129 | 163 | 152 | |
Total Liabilities | 136 | 163 | 168 | 193 | 189 | 209 | 240 | 326 | 333 | 347 | 405 | 446 |
10 | 12 | 9 | 18 | 17 | 17 | 21 | 84 | 71 | 61 | 53 | 49 | |
CWIP | 3 | 0 | 0 | 0 | 0 | 6 | 34 | 0 | 0 | 0 | 0 | 0 |
Investments | 19 | 27 | 43 | 43 | 70 | 66 | 39 | 80 | 31 | 43 | 91 | 97 |
104 | 124 | 116 | 131 | 101 | 120 | 147 | 163 | 230 | 243 | 261 | 300 | |
Total Assets | 136 | 163 | 168 | 193 | 189 | 209 | 240 | 326 | 333 | 347 | 405 | 446 |
Cash Flows
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
2 | 15 | 19 | 16 | 26 | 2 | 7 | 49 | -19 | 29 | 54 | 13 | |
4 | -5 | -12 | -5 | -20 | 2 | 3 | -77 | 52 | -8 | -43 | 1 | |
-6 | -8 | -8 | -9 | -4 | -5 | -7 | 22 | -33 | -19 | -12 | -9 | |
Net Cash Flow | -0 | 2 | -1 | 2 | 2 | -1 | 3 | -5 | 0 | 2 | -2 | 5 |
Ratios
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 82 | 102 | 88 | 84 | 100 | 109 | 85 | 96 | 90 | 102 | 118 | 107 |
Inventory Days | 43 | 33 | 27 | 35 | 72 | 64 | 64 | 98 | 90 | 77 | 66 | 57 |
Days Payable | 86 | 102 | 79 | 77 | 102 | 105 | 89 | 166 | 133 | 117 | 139 | 105 |
Cash Conversion Cycle | 39 | 33 | 36 | 42 | 70 | 68 | 61 | 28 | 48 | 62 | 46 | 58 |
Working Capital Days | 45 | 42 | 43 | 51 | 79 | 83 | 70 | 44 | 68 | 70 | 61 | 99 |
ROCE % | 26% | 31% | 33% | 35% | 19% | 14% | 19% | 10% | 16% | 18% | 19% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
2d - Newspaper publication of the Audited Financial Results for the Quarter and Year ended 31st March, 2024, published in the Financial Express in English Language and …
- Results-Financial Year Ended 31St March, 2024 17 May
- Announcement under Regulation 30 (LODR)-Change in Management 17 May
- Board Meeting Outcome for Board Meeting Outcome Board Meeting Held On 17/05/2024 17 May
- Board Meeting Intimation for Consideration And Approval Of Audited Financial Results For The Financial Year Ended 31St March, 2024 And Recommendation Of Final Dividend, If Any, For The Financial Year 2023-24. 9 May
Annual reports
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
-
Financial Year 2009
from bse
Concalls
-
Feb 2024TranscriptNotesPPT
-
Aug 2023TranscriptNotesPPT
-
Jun 2023TranscriptNotesPPT
-
Feb 2023TranscriptNotesPPT
-
Aug 2022TranscriptNotesPPT
-
May 2022Transcript PPT
-
Feb 2022Transcript PPT
-
Feb 2022TranscriptNotesPPT
-
Nov 2021Transcript PPT
-
Aug 2021Transcript PPT
-
May 2021TranscriptNotesPPT
-
Feb 2021Transcript PPT
-
Feb 2021TranscriptNotesPPT
-
Nov 2020TranscriptNotesPPT
-
Aug 2020TranscriptNotesPPT
-
Jun 2020TranscriptNotesPPT
-
Aug 2019TranscriptNotesPPT
-
Dec 2017TranscriptNotesPPT
-
Feb 2016TranscriptNotesPPT
-
Dec 2015TranscriptNotesPPT
-
Sep 2015TranscriptNotesPPT
-
Aug 2015TranscriptNotesPPT
Business Highlights[1]
Anuh Pharma Limited is one of the largest producer of Erythromycin 1st generation salts and pyrazinamide in the world. Anuh Pharma is
also one of the very few to have WHO PQ for sulphadoxine and have applied WHO PQ for Pyrimethamine (Anti malaria).
The Company has over 350 customers in over 57 countries including Europe, Mexico and South Africa